- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07944716
Function-Friendly Semi-Fowler Positioning for Coronary Angiography and PCI
Pilot Study on the Feasibility and Safety of Function-Friendly Semi-Fowler Positioning in Coronary Angiography and Percutaneous Coronary Intervention
This study will assess whether planned coronary angiography (CAG), and simple percutaneous coronary intervention (PCI) when needed, can be completed safely and technically while participants are in a semi-sitting position with the head of the procedure table raised to 60 degrees. Ten clinically stable adults scheduled for an elective procedure are planned. The first stage will include participants undergoing CAG. After a safety review, the study may include participants expected to need only simple PCI. Heart rhythm, blood pressure, and blood oxygen will be monitored continuously. If predefined safety criteria occur, staff will lower the table or return the participant to a flat position and provide usual clinical care. Researchers will describe procedure completion, image quality, radiation exposure, contrast use, tolerance of the position, and safety events through 3 days after the procedure. This exploratory study is not designed to establish treatment efficacy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, single-center, open-label, single-arm, staged early-feasibility study at Zhongshan Hospital, Fudan University. The planned enrollment is 10 participants aged 18 to 75 years. Eligible participants are clinically stable and scheduled for elective transradial CAG or planned simple PCI, and can tolerate a monitored 60-degree semi-Fowler position for at least 10 minutes before the procedure. The first stage prioritizes CAG. Participants expected to need only simple PCI may be enrolled only after a safety review confirms that the workflow is executable without unacceptable risk. During CAG and, when clinically indicated, simple PCI, the procedure table will be raised to a default head elevation of 60 degrees. ECG, blood pressure, and oxygen saturation will be monitored continuously. If chest pain, significant dyspnea, persistent oxygen saturation below 90%, systolic blood pressure below 90 mmHg or a decrease of at least 30% requiring intervention, sustained ventricular tachycardia or fibrillation, cerebral hypoperfusion, equipment collision, catheter or tubing traction, or another predefined safety concern occurs, the positioning intervention will stop and the table will be lowered or the participant returned to 0-degree supine; usual clinical care will take priority. CAG and PCI technical success will be described among participants undergoing the respective procedure. Safety events will be collected from the start of the positioning intervention through 3 days after the procedure. Other measures include image quality, completion of standard projections, fluoroscopy time, dose-area product, contrast volume, procedure duration, positioning changes, and tolerance. No investigational drug is used. The commercial angiography X-ray system is used as a carrier for the positioning intervention; the study does not modify or evaluate the device.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Cong Wang
- Phone Number: +86 13671683698
- Email: kelindunzizhuan@126.com
Study Locations
-
-
-
Shanghai, China
- Zhongshan Hospital, Fudan University
-
Contact:
- Cong Wang
- Phone Number: +86 13671683698
- Email: kelindunzizhuan@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 to 75 years.
- Clinically stable and scheduled for elective coronary angiography (CAG) or planned simple percutaneous coronary intervention (PCI), with no ongoing resting ischemia.
- Meets clinical indications for coronary angiography or intervention, with ischemic evidence consistent with coronary artery disease based on symptoms, ECG, or noninvasive imaging.
- Planned radial access; the operator expects the procedure can be performed using standard catheters and devices.
- Able to tolerate a monitored 60-degree semi-Fowler position for at least 10 minutes before the procedure.
- Body size, weight, shoulder width, and range of motion are within equipment and support-system limits, and the participant can be secured using the manufacturer-approved fixation system.
- Able to understand the study and provide written informed consent.
Exclusion Criteria:
- Pregnant or breastfeeding, or the participant or spouse plans pregnancy within the next 6 months.
- Known contraindication to local anesthetic or history of severe contrast-media allergy.
- Neurologic or psychiatric disease or language impairment that prevents effective communication or cooperation.
- Serious comorbidity with expected survival less than 6 months.
- Uncontrolled hypertension (screening systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg) or baseline systolic blood pressure <100 mmHg.
- Acute coronary syndrome, ongoing ischemia, hemodynamic instability, cardiogenic shock, or need for emergency CAG/PCI.
- Decompensated heart failure, left ventricular ejection fraction <30%, inability to maintain oxygenation at rest, or estimated glomerular filtration rate <30 mL/min/1.73 m^2.
- Known or highly suspected high-risk left main disease, chronic total occlusion, complex bifurcation disease, severe calcification, or other anatomy expected to require complex PCI.
- Platelet count <50 × 10^9/L or coagulation results outside the institution usual acceptable range.
- Participation in another clinical trial or research study within 2 months before screening.
- Back pain, stiffness, limited mobility, or injury preventing tolerance of transition from supine to the study position.
- Inability to secure the torso reliably, inability to complete the pre-procedure positioning-tolerance test, or investigator judgment that emergency return to supine may be restricted.
- Any other condition for which the investigator considers participation unsafe.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Function-Friendly Semi-Fowler Positioning
All participants receive the same positioning intervention during elective transradial CAG and, if clinically indicated, simple PCI. The procedure table is raised to a default head elevation of 60 degrees, with continuous ECG, blood pressure, and oxygen saturation monitoring. If predefined safety concerns occur, the table angle is lowered or the participant is returned to 0-degree supine and usual clinical care is provided. |
The procedure table head is elevated to a default 60-degree semi-Fowler position during elective transradial coronary angiography and, if clinically indicated, simple PCI. ECG, blood pressure, and oxygen saturation are continuously monitored. If predefined safety criteria occur, the table angle is reduced or the participant is immediately returned to 0-degree supine and usual clinical care is provided. The commercial angiography X-ray system and adjustable procedure table are used as available clinical equipment; no device hardware, software, collision protection, interlocks, image processing, or dose-control functions are modified or evaluated. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Participants With Coronary Angiography (CAG) Technical Success
Time Frame: During the CAG procedure
|
The number of participants undergoing CAG who complete the planned CAG in the prespecified semi-Fowler position without position-related unplanned return to supine or substantial angle reduction, procedure discontinuation, access-site change, missing key projections, or participant/equipment collision, and whose images are independently confirmed to be diagnostic, divided by the number of participants undergoing CAG. |
During the CAG procedure
|
|
Proportion of Participants With Percutaneous Coronary Intervention (PCI) Technical Success
Time Frame: During the PCI procedure
|
Among participants who undergo PCI, the proportion who complete planned device delivery, treatment, and withdrawal while meeting the protocol-defined positioning and safety requirements. PCI success is calculated using participants who undergo PCI as the denominator. |
During the PCI procedure
|
|
Participants With Position-Related Serious Adverse Events or Prespecified Safety Events
Time Frame: From the start of the positioning intervention through 3 days after the procedure
|
Number and proportion of participants experiencing a position-related serious adverse event or any prespecified safety event: hemodynamic instability, hypoxia, sustained arrhythmia, cerebral hypoperfusion, unplanned respiratory or circulatory support, mechanical collision, or emergency return to supine. |
From the start of the positioning intervention through 3 days after the procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic Acceptability of Coronary Angiography Images
Time Frame: During the procedure
|
Coronary angiography and fluoroscopy image quality rated on a 1-to-3 Likert scale; a score of 2 or 3 is acceptable. Images are assessed by two independent physicians, with adjudication by a third if needed. |
During the procedure
|
|
Completion of Standard Coronary Angiographic Views and Visualization of Major Coronary Segments
Time Frame: During the procedure
|
Completion of standard left anterior oblique, right anterior oblique, cranial, and caudal projections, and the ability to visualize the left anterior descending, left circumflex, and right coronary arteries and their major branches. |
During the procedure
|
|
Total Fluoroscopy Time
Time Frame: During the procedure
|
Total fluoroscopy time recorded during the CAG and, if performed, PCI procedure. |
During the procedure
|
|
Dose-Area Product (DAP)
Time Frame: During the procedure
|
Dose-area product and other radiation dose parameters recorded by the angiography system. |
During the procedure
|
|
Contrast Volume
Time Frame: During the procedure
|
Total contrast-media volume administered during the procedure. |
During the procedure
|
|
Procedure Duration
Time Frame: During the procedure
|
Total duration of the CAG procedure and, if performed, PCI procedure, recorded as specified in the study CRF. |
During the procedure
|
|
Positioning Tolerance and Adjustments
Time Frame: During the procedure
|
Table-head angle, number and reasons for position adjustments, participant symptoms, unplanned return to 0-degree supine, and equipment collision events. |
During the procedure
|
|
Access and Device Delivery Completion
Time Frame: During the procedure
|
Successful radial artery access and completion of planned device delivery and withdrawal, as applicable to the procedure performed. |
During the procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Junbo Ge, Fudan University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY2026343
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The protocol states that any data sharing must use de-identified data and receive the required approvals. Whether individual participant data will be shared, and the timing, access process, and supporting information, have not yet been determined.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.